Last Price$19.1(7.5%)
Market Cap$14.6B
P/FCF LTM
(115.2x)
5Y avg
(27.3x)
Biotechnology industry
median
(2.0x)
Stock quality & Intrinsic value
6/10
(1.0%) overvalued
Summit Therapeutics Inc. P/FCF LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| P/FCF LTM | (17.4x) | 7.0x | (7.9x) | (2.2x) | (1.7x) | (7.8x) | (3.4x) | (15.8x) | (35.7x) | (115.2x) |
Overvalued or undervalued?
Check the intrinsic value for SMMT
and see if it's the right time to invest.
Summit Therapeutics Inc. (SMMT) P/FCF LTM comparison analysis
General
LTM P/FCF LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Summit Therapeutics Inc.SMMT
(102.6x)
N/A
(68.7%)
N/A
Median Peer Set
9.2x
18.9%
(41.2%)
12.6%
Incyte CorporationINCY
62.8x
14.8%
(94.0%)
0.8%
Novo Nordisk A/SNVO
41.2x
24.9%
142.8%
34.8%
BioNTech SEBNTX
26.3x
(77.4%)
(89.7%)
24.4%
Regeneron Pharmaceuticals, Inc.REGN
20.6x
8.3%
10.4%
31.1%
United Therapeutics CorporationUTHR
13.0x
23.6%
25.7%
41.5%
Royalty Pharma plcRPRX
5.5x
(3.8%)
(43.7%)
37.9%
BeiGene, Ltd.BGNE
(1.8x)
73.7%
(56.5%)
(35.9%)
Vertex Pharmaceuticals IncorporatedVRTX
(158.8x)
11.7%
N/A
(4.9%)
argenx SEARGX
(180.5x)
198.6%
(60.5%)
(24.1%)
Alnylam Pharmaceuticals, Inc.ALNY
(735.2x)
23.0%
(38.6%)
(12.4%)
SMMT key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1.7 338.9% | 3.8 119.8% | 12.1 219.9% | 0.5 (96.0%) | 0.5 (1.1%) | 1.9 290.6% | 4.4 138.3% | 4.6 2.5% | 3.6 (21.8%) | 3.7 4.3% | 0.0 (100.0%) | 3.9 0.0% | 46.8 1,114.8% | 74.9 59.9% | 0.8 (98.9%) | 0.9 6.6% | 1.8 110.3% | 0.7 (61.1%) | 0.0 (100.0%) | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.8 | 1.1 | 5.0 | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 2.5 | 2.1 | 15.0 |
% margin | 1.0 56.1% | 2.7 70.6% | 7.0 58.3% | 0.5 97.8% | 0.5 100.0% | 1.9 100.0% | 2.8 63.7% | 4.6 100.0% | 3.6 100.0% | 3.7 100.0% | 0.0 0.0% | 3.9 100.0% | 46.7 99.7% | 74.8 100.0% | 0.6 75.4% | 0.9 100.0% | 1.8 100.0% | (1.8) (257.0%) | (2.1) 0.0% | (15.0) 0.0% |
| Operating Expenses | 6.8 | 18.6 | 53.9 | 27.9 | 15.0 | 8.6 | 11.9 | 13.5 | 20.9 | 31.6 | 44.8 | 45.4 | 70.4 | 63.3 | 53.6 | 53.2 | 88.0 | 64.3 | 87.7 | 211.3 |
| Research & Development Expenses (R&D) | 3.3 | 10.8 | 30.7 | 13.3 | 5.8 | 5.7 | 7.7 | 9.1 | 17.0 | 25.6 | 36.4 | 31.7 | 53.4 | 68.2 | 41.7 | 53.3 | 85.4 | 52.0 | 59.5 | 150.8 |
| Selling, General & Administrative Expenses (SG&A) | 3.2 | 3.5 | 14.6 | 9.1 | 6.6 | 4.1 | 3.7 | 4.4 | 5.1 | 11.1 | 11.3 | 13.8 | 22.1 | 21.5 | 11.9 | 19.2 | 23.6 | 26.7 | 28.2 | 60.5 |
% margin | (5.8) (338.9%) | (16.0) (423.8%) | (46.9) (388.4%) | (34.7) (7,198.9%) | (14.5) (3,047.6%) | (14.5) (777.1%) | (7.6) (170.1%) | (11.5) (252.3%) | (17.4) (487.9%) | (31.3) (844.4%) | (43.7) 0.0% | (41.6) (1,078.7%) | (23.7) (50.7%) | 16.4 21.9% | (54.6) (6,766.4%) | (53.2) (6,185.2%) | (86.2) (4,764.3%) | (72.1) (10,235.6%) | (89.7) 0.0% | 0.3 0.0% |
| Interest Income | 1.9 | 3.2 | 3.1 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.7 | 4.9 | 0.0 | 0.0 | 0.2 | 1.5 | 10.4 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 1.4 | 2.1 | 0.7 | 0.0 | 0.3 | 0.3 | 4.4 | 16.5 | (8.7) |
| Pre-tax Income | (3.9) | (12.8) | (43.9) | (34.2) | (14.7) | (14.4) | (7.5) | (11.5) | (17.3) | (31.2) | (43.7) | (43.0) | (20.1) | 8.8 | (36.3) | (52.9) | (88.6) | (78.8) | (615.9) | (221.3) |
% effective tax rate | (0.5) 12.8% | (1.8) 13.9% | (3.6) 8.3% | (4.6) 13.3% | (0.9) 6.4% | (3.0) 20.7% | (0.8) 10.1% | (0.9) 7.5% | (1.6) 9.1% | (3.2) 10.2% | (6.6) 15.2% | (7.3) 16.9% | (6.9) 34.5% | (4.3) (49.6%) | (5.8) 15.9% | (0.2) 0.4% | (2.5) 2.8% | (4.4) 5.6% | (0.9) 0.2% | 0.0 0.0% |
% margin | (3.4) (199.7%) | (11.0) (292.1%) | (40.3) (334.1%) | (58.4) (12,109.8%) | (13.7) (2,867.2%) | (11.4) (614.7%) | (6.8) (152.6%) | (10.6) (232.9%) | (15.8) (443.1%) | (28.0) (754.9%) | (37.0) 0.0% | (35.7) (927.6%) | (13.1) (28.1%) | 13.1 17.5% | (30.5) (3,779.1%) | (52.7) (6,127.6%) | (86.1) (4,762.1%) | (74.4) (10,561.1%) | (614.9) 0.0% | (221.3) 0.0% |
| EPS | (0.11) | (0.30) | (0.84) | (1.09) | (0.21) | (0.07) | (0.04) | (0.67) | (3.26) | (0.70) | (0.62) | (0.58) | (0.21) | 0.15 | (0.19) | (0.76) | (0.93) | (0.38) | (0.99) | (0.31) |
| Diluted EPS | (0.11) | (0.30) | (0.84) | (1.09) | (0.21) | (0.07) | (0.04) | (0.67) | (3.26) | (0.70) | (0.62) | (0.58) | (0.20) | 0.15 | (0.19) | (0.76) | (0.93) | (0.38) | (0.99) | (0.31) |
% margin | (5.4) (313.6%) | (11.4) (302.4%) | (37.2) (308.4%) | (29.0) (6,010.3%) | (8.5) (1,790.5%) | (13.3) (716.0%) | (7.1) (159.0%) | (8.7) (191.3%) | (17.3) (486.0%) | (20.0) (537.9%) | (30.9) 0.0% | (41.5) (1,075.8%) | (41.9) (89.5%) | 15.5 20.7% | (21.4) (2,657.4%) | (37.1) (4,317.9%) | (62.7) (3,468.0%) | (52.6) (7,472.8%) | 1.0 0.0% | 0.3 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Summit Therapeutics Inc.'s P/FCF LTM?
As of today, Microsoft Corp's last 12-month P/FCF LTM is (115.2x), based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/FCF LTM for Summit Therapeutics Inc. have been (35.8x) over the past three years, and (28.7x) over the past five years.
2) Is Summit Therapeutics Inc.'s P/FCF LTM Good?
As of today, Summit Therapeutics Inc.'s P/FCF LTM is (115.2x), which is lower than industry median of (2.0x). It indicates that Summit Therapeutics Inc.'s P/FCF LTM is Good.